Aethlon Medical (AEMD) is merging with privately held North Immunology in an all-stock transaction, with AEMD shareholders retaining only 4.75% of the combined entity. This reverse merger is coupled with an oversubscribed $180 million private placement, positioning the new company to fund its lead drug candidate, NOR-101, into late 2028.
Aethlon Medical (AEMD) is undergoing a reverse merger with North Immunology, a privately held biotechnology company. This is a transformative event for AEMD, as existing shareholders will own a significantly diluted stake (4.75%) in the combined entity, which will operate under the North Immunology name and new ticker NRTX. The merger is accompanied by a substantial $180 million private placement, providing critical funding for North Immunology's lead drug candidate, NOR-101, through H2 2028. This move effectively transforms AEMD into a vehicle for North Immunology's clinical development, offering AEMD shareholders a speculative opportunity in a new biotech venture while largely divesting from Aethlon's legacy assets (though CVRs are offered). For traders, the short-term impact on AEMD could be volatile due to the significant ownership change and the speculative nature of early-stage biotech, while the long-term hinges on NOR-101's clinical trial success.